Myozyme Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to recognition of pompe disease as a treatable condition, regulatory approvals for enzyme replacement therapies, expansion of rare disease awareness programs, development of recombinant enzyme technologies, establishment of specialty treatment centers.

The growth in the forecast period can be attributed to increasing investments in rare disease research, rising demand for next-generation enzyme therapies, expansion of personalized treatment approaches, growing focus on pediatric rare disease management, advancements in biologics manufacturing technologies. Major trends in the forecast period include increasing adoption of enzyme replacement therapies, rising focus on rare disease treatment solutions, growing demand for long-term pompe disease management, expansion of biologic drug manufacturing capabilities, enhanced patient access programs for orphan drugs.

The growing incidence of rare genetic disorders is anticipated to support the expansion of the myozyme market in the coming years. Rare genetic disorders are infrequent inherited conditions caused by gene mutations and typically affect a small segment of the population. The increasing incidence of these disorders is linked to factors such as genetic mutations, advancements in genetic testing, and overall population growth. Myozyme is used to manage symptoms of Pompe disease by replacing the missing enzyme, helping to extend patient life expectancy and enhance quality of life. As a greater number of individuals with Pompe disease receive treatment, improved survival rates and health outcomes contribute to rising demand for myozyme in the management of these conditions. For instance, in July 2025, according to the Adult Polyglucosan Body Disease (APBD) Research Foundation, a US-based nonprofit organization focused exclusively on advancing research, a recent study on 1,4-alpha-glucan branching enzyme 1 (GBE1)-related rare genetic diseases revised the global prevalence estimate from 1 in 325,000 in 2022 to 1 in 236,000 in 2025, indicating that approximately 34,000 people worldwide may be affected, reflecting improved detection and data availability for these rare disorders. Therefore, the increasing incidence of rare genetic disorders is contributing to the growth of the myozyme market.

The increasing adoption of telemedicine is expected to contribute to the growth of the myozyme market in the future. Telemedicine involves the use of digital communication technologies to deliver healthcare services remotely, including medical consultations, diagnoses, and treatment monitoring. The growing use of telemedicine is driven by improved access to healthcare, enhanced convenience for patients, and notable cost savings for both healthcare providers and patients. Telemedicine allows for more frequent and accessible interactions between patients and healthcare professionals. Early diagnosis of conditions such as Pompe disease, which is treated with myozyme, is essential for effective therapy. By enabling faster diagnosis and timely medical intervention, telemedicine can increase demand for myozyme as more patients begin treatment at earlier stages. For example, in February 2025, according to the American Hospital Association, a US-based national organization representing hospitals and health systems, more than 12.6% of Medicare beneficiaries used telehealth services in the fourth quarter of 2023. Therefore, the growing adoption of telemedicine is supporting the expansion of the myozyme market.

The increase in healthcare investment is expected to fuel the growth of the myozyme market going forward. Healthcare investment refers to the allocation of resources toward developing, enhancing, and sustaining the physical, technological, and organizational infrastructure required for effective healthcare delivery. Investment in healthcare is rising due to factors such as increasing demand for services, the need for pandemic preparedness, efforts to improve health outcomes, and the goal of expanding access and equity. Greater healthcare investment strengthens the capacity to develop specialized therapies such as myozyme and supports the research, development, and availability of life-saving treatments for rare diseases. For instance, in May 2023, according to the American Health Care Association, a US-based nonprofit organization, the United States had 6,129 hospitals, marking a 0.591% increase from the previous year when 6,093 hospitals were reported. Therefore, the rise in healthcare investment is contributing to the growth of the myozyme market.

Major companies operating in the myozyme market are Sanofi S.A.

North America was the largest region in the myozyme market in 2025. The regions covered in the myozyme market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the myozyme market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the myozyme market by increasing costs of imported biologic raw materials, cell culture media, specialized manufacturing equipment, and cold-chain logistics used in enzyme replacement therapy production. North America and Europe are most affected due to cross-border sourcing of biologic inputs, while Asia-Pacific faces higher costs in import-dependent distribution networks. These tariffs are raising treatment costs and influencing pricing negotiations with healthcare providers. However, they are also encouraging localized biologics manufacturing, regional supply chain optimization, and increased investment in domestic rare disease drug production.

The myozyme market research report is one of a series of new reports that provides myozyme market statistics, including myozyme industry global market size, regional shares, competitors with a myozyme market share, detailed myozyme market segments, market trends and opportunities, and any further data you may need to thrive in the myozyme industry. This myozyme market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Myozyme is a powdered drug that is prepared as a solution for infusion and administered via intravenous drip. It contains the active ingredient alglucosidase alfa, an enzyme replacement therapy used in the management of Pompe disease, a rare inherited condition. Myozyme works by supplementing the deficient enzyme and helping to alleviate disease-related symptoms.

The primary indication for Myozyme is the treatment of Pompe disease and other glycogen storage disorders. Management of Pompe disease centers on enzyme replacement therapy (ERT), mainly using Myozyme, to compensate for the missing enzyme in affected individuals with this rare genetic condition. The end users include hospitals, specialty clinics, research institutions, and homecare settings. Distribution channels include hospital pharmacies, specialty pharmacies, retail pharmacies, online pharmacies, as well as government and public health programs. The treated age groups comprise pediatric and adult patients.

The myozyme market consists of the sale of pre-filled syringes, intravenous infusion, and vials. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.